Recent Posts on This Topic | See All >
InNexus Biotechnology awarded federal grantTags: cancer
[Source: Finacial Times] - InNexus Biotechnology Inc., a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL™) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company’s development of DXL™ anti-cancer antibodies.
For more information: InNexus Biotechnology Awarded Federal Grant
Now available: “Arizona’s Bioscience Roadmap 2014-2025: Advancing the Biosciences and Improving Health Outcomes,” is now available along with its supplement, “Summary of Goals, Strategies, and Potential Actions.” An overview by Walter Plosila, Ph.D., Battelle senior advisor, is also available. The updated Roadmap provides a long-term strategy for Arizona to achieve bioscience success over the next decade.